KLP Kapitalforvaltning’s Soleno Therapeutics SLNO Stock Holding History

KLP Kapitalforvaltning’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,600	Closed	-$355K	–	2193
2026 Q1	$355K	Buy	10,600 +600	+6%	+$23.5K	﹤0.01%	1584
2025 Q4	$463K	Buy	10,000 +1,700	+20%	+$93.2K	﹤0.01%	1455
2025 Q3	$561K	Buy	8,300 +1,300	+19%	+$96.4K	﹤0.01%	1336
2025 Q2	$586K	Buy	7,000 +2,700	+63%	+$202K	﹤0.01%	1282
2025 Q1	$307K	Hold	4,300	–	–	﹤0.01%	1551
2024 Q4	$193K	Buy	+4,300	New	+$223K	﹤0.01%	1836

KLP Kapitalforvaltning's SLNO Position: Q2 2026 in Review

KLP Kapitalforvaltning sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 10,600 shares — an estimated $355K sold.

KLP Kapitalforvaltning first reported a position in SLNO in Q4 2024 and held it in 6 quarters. The position peaked at $586K in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

KLP Kapitalforvaltning reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
KLP Kapitalforvaltning sold 10,600 Soleno Therapeutics shares in Q2 2026, an estimated $355K.
KLP Kapitalforvaltning first reported a position in Soleno Therapeutics in Q4 2024 and held it in 6 quarters.
KLP Kapitalforvaltning's Soleno Therapeutics position peaked at $586K in Q2 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.